Epidemiology and Etiology of Schizophrenia

Abstract

The present landscape of therapy options for schizophrenia includes a large number of well-established atypical antipsychotic drugs. These medicines may assist in the management of positive symptoms of the condition, such as hallucination, delusion, and disordered speech. On the other hand, this is only successful in treating a subset of individuals. In addition, the influence of antipsychotic medicine that is currently on the market has a little effect on the cognitive plus negative schizophrenia symptoms. As a consequence of this, the market for schizophrenia requires treatments that use innovative mechanisms of action. At the present, every atypical antipsychotic medicine target dopaminergic transmission, and as a result, they all have a comparable effectiveness profile when it comes to lessening the intensity of psychotic actions and thoughts. The protection profiles of these two options vary from one another in only very minor ways. Unfortunately, not all patients respond well to atypical antipsychotic medication.